| Filed On | Filing |
|---|---|
| 07 Dec 2023 |
8-K/A: Financial Statements and Exhibits
See accompanying notes to unaudited consolidated financial statements. |
| 14 Sep 2023 |
8-K/A: Entry into a Material Definitive Agreement
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of August 14, 2023, by and among: Harmony Biosciences Holdings, Inc., a Delaware corporation (“Parent”); Xylophone Acquisition Corp., a Delaware corporation... |
| 31 May 2023 |
8-K/A: Departure/Election of Directors or Officers; Compensation
The Company previously announced that Dr. Dayno accepted his appointment as the President and CEO of the Company. Effective on May 26, 2023, the Company granted Dr. Dayno 125,000 options (the “Option”) pursuant to the Company’s amended 2... |
| 23 Jan 2023 |
8-K/A: Departure/Election of Directors or Officers; Compensation
US-DOCS\138339073.5 HARMONY BIOSCIENCES HOLDINGS, INC. January 23, 2023 Jeffrey M. Dayno, M.D. [email protected] Re: Interim President and Chief Executive Officer Role Dear Mr. Dayno: As you know, on January 6, 2023, the Boar... |
| 28 Sep 2022 |
8-K/A: Submission of Matters to a Vote of Security Holders
On May 20, 2022, the Company held its 2022 Annual Meeting. At the Annual Meeting, stockholders voted on the following three proposals, each of which is described in detail in the Company's definitive proxy statement filed with the Securi... |
Loading...
